Paul Richard Kaesberg

Title(s)Professor, Hematology and Oncology
SchoolSchool of Medicine
AddressCancer Ctr So, #3016
CA 95817
Phone916-734-3772
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 09; 20(9):1033-1062. Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. PMID: 36075392.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    2. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. Leuk Res. 2022 08; 119:106885. Othman T, Moskoff BN, Ho G, Tenold ME, Azenkot T, Krackeler ML, Fisch SC, Potter LA, Kaesberg PR, Welborn JL, Wun T, Esteghamat NS, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. PMID: 35738024.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    3. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw. 2022 06; 20(6):622-634. Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. PMID: 35714675.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    4. Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. Clin Cancer Res. 2021 09 01; 27(17):4726-4736. Tuscano JM, Poh C, Kaesberg P, Luxardi G, Merleev A, Marusina A, Brunson A, Rosenberg A, Jonas B, Maverakis E. PMID: 34088724; PMCID: PMC9262142.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    5. Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia. J Hematol. 2020 Sep; 9(3):79-83. Tuscano J, Poh C, Rosenberg A, Jonas B, Abedi M, Barisone G, Schwab E, Lundeberg K, Kaesberg P. PMID: 32855756; PMCID: PMC7430864.
      View in: PubMed   Mentions: 1  
    6. Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. Leuk Lymphoma. 2020 02; 61(2):309-317. Siddiqi T, Frankel P, Beumer JH, Kiesel BF, Christner S, Ruel C, Song JY, Chen R, Kelly KR, Ailawadhi S, Kaesberg P, Popplewell L, Puverel S, Piekarz R, Forman SJ, Newman EM. PMID: 31617432; PMCID: PMC6982547.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    7. Patients' Hopes for Advanced Cancer Treatment. J Pain Symptom Manage. 2019 01; 57(1):57-63.e2. DeMartini J, Fenton JJ, Epstein R, Duberstein P, Cipri C, Tancredi D, Xing G, Kaesberg P, Kravitz RL. PMID: 30261227; PMCID: PMC6310622.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    8. Effect of a Patient-Centered Communication Intervention on Oncologist-Patient Communication, Quality of Life, and Health Care Utilization in Advanced Cancer: The VOICE Randomized Clinical Trial. JAMA Oncol. 2017 Jan 01; 3(1):92-100. Epstein RM, Duberstein PR, Fenton JJ, Fiscella K, Hoerger M, Tancredi DJ, Xing G, Gramling R, Mohile S, Franks P, Kaesberg P, Plumb S, Cipri CS, Street RL, Shields CG, Back AL, Butow P, Walczak A, Tattersall M, Venuti A, Sullivan P, Robinson M, Hoh B, Lewis L, Kravitz RL. PMID: 27612178; PMCID: PMC5832439.
      View in: PubMed   Mentions: 154     Fields:    Translation:Humans
    9. Values and options in cancer care (VOICE): study design and rationale for a patient-centered communication and decision-making intervention for physicians, patients with advanced cancer, and their caregivers. BMC Cancer. 2013 Apr 09; 13:188. Hoerger M, Epstein RM, Winters PC, Fiscella K, Duberstein PR, Gramling R, Butow PN, Mohile SG, Kaesberg PR, Tang W, Plumb S, Walczak A, Back AL, Tancredi D, Venuti A, Cipri C, Escalera G, Ferro C, Gaudion D, Hoh B, Leatherwood B, Lewis L, Robinson M, Sullivan P, Kravitz RL. PMID: 23570278; PMCID: PMC3637237.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    10. Effects of sized heparin oligosaccharide on the interactions of Chinese hamster ovary cell with thrombospondin. Semin Thromb Hemost. 1992; 18(2):243-51. Sun X, Kaesberg PR, Choay J, Harenberg J, Ershler WB, Mosher DF. PMID: 1631572.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    11. Biology of cancer and aging. Cancer. 1991 Dec 01; 68(11 Suppl):2525-6. Holmes FF, Wilson J, Blesch KS, Kaesberg PR, Miller R, Sprott R. PMID: 1933796.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. The importance of immunesenescence in the incidence and malignant properties of cancer in hosts of advanced age. J Gerontol. 1989 Nov; 44(6):63-6. Kaesberg PR, Ershler WB. PMID: 2681365.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    13. Chinese hamster ovary cell adhesion to human platelet thrombospondin is dependent on cell surface heparan sulfate proteoglycan. J Clin Invest. 1989 Mar; 83(3):994-1001. Kaesberg PR, Ershler WB, Esko JD, Mosher DF. PMID: 2522106; PMCID: PMC303776.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    14. The change in tumor aggressiveness with age: lessons from experimental animals. Semin Oncol. 1989 Feb; 16(1):28-33. Kaesberg PR, Ershler WB. PMID: 2645646.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    15. Concurrent development of a thymic cyst and mediastinal Hodgkin's disease. Med Pediatr Oncol. 1988; 16(4):293-4. Kaesberg PR, Foley DB, Pellett J, Hafez GR, Ershler WB. PMID: 3419396.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    With one click, see people who:

    Mentor

    Offer Student Projects

    Run Clinical Trials

    See more options in the Advanced Search tab

    Paul's Networks
    Concepts (99)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (21)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UC Davis Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California